A Pilot Trial for Prevention of Hepatitis C Virus Transmission From Donor to Organ Transplant Recipient With Short-Course Glecaprevir/Pibrentasvir

Open Forum Infect Dis. 2022 Oct 27;9(11):ofac550. doi: 10.1093/ofid/ofac550. eCollection 2022 Nov.

Abstract

A 7-day course of glecaprevir/pibrentasvir started in the preoperative period prevented transmission of hepatitis C virus (HCV) from viremic donors to 10 HCV-negative recipients (2 heart, 1 lung, 6 kidney, 1 heart/kidney) with 100% sustained virological response at 12 weeks.

Keywords: DAA; HCV; direct-acting antiviral; donor-derived infection; glecaprevir/pibrentasvir; prophylaxis.